Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
March 28, 2022--Company to Host Conference Call March 31, 2022, at 8:30AM ET---
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report year end 2021 financial results prior to...
-
March 18, 2022
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage pharmaceutical company, announced today that the company's Board of Directors appointed Ira Strassberg as Chief Financial Officer and...
-
March 8, 2022Robert Besthof, Head of Operations and Chief Commercial Officer, Appointed Interim CEO Jonathan Javitt, MD, MPH, to Serve as a Consultant and Chief Scientist and Remain on the Board of Directors
NRx Pharmaceuticals (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage, biopharmaceutical company, today announced that Jonathan Javitt, MD, MPH, has retired as Chief Executive Officer...
-
February 15, 2022- After review of more than 448 enrolled patients in ACTIV-3b Critical Care Study, no new safety concerns identified by Independent Data Safety Monitoring Board; study cleared to continue enrollment to 640 Patients
NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board...
-
February 11, 2022•Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaper
RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the...
-
February 2, 2022
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has closed its previously announced private placement priced at a premium to market...
-
January 30, 2022
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of...
-
January 27, 2022- Israel Institute for Biological Research files initial scientific results of BriLife vaccine effectiveness in producing neutralizing antibody against Omicron Variant
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine...
-
January 26, 2022-A Southwestern hospital has reported safety data collected under the Federal Right to Try law indicating that 16 of 19 patients (84%) with COVID-19 respiratory failure treated with ZYESAMI® by Dec 31, 2021 have survived the ICU.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI®...
-
January 18, 2022•ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)
RADNOR, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) today announced enhancements to its Expanded Access and Right to Try programs. The programs enable patients with...
Click here to view our corporate presentation or on the image below
![]() |